PFEPFIZER INC

NYSE pfizer.com


$ 28.72 $ 0.52 (1.84 %)    

Friday, 31-May-2024 10:42:15 EDT
QQQ $ 454.82 $ -4.76 (-1.05 %)
DIA $ 398.57 $ -0.24 (-0.06 %)
SPY $ 530.36 $ -3.78 (-0.72 %)
TLT $ 91.26 $ 0.09 (0.1 %)
GLD $ 225.37 $ -1.09 (-0.5 %)
$ 28.2
$ 28.25
$ 28.70 x 600
$ 28.73 x 500
$ 28.25 - $ 28.73
$ 24.83 - $ 38.23
23,330,710
na
160.66B
$ 0.58
nm
TBD
na
na ($ 0.06)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-08-2023 10-01-2023 10-Q
4 08-09-2023 07-02-2023 10-Q
5 05-10-2023 04-02-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-09-2022 10-02-2022 10-Q
8 08-10-2022 07-03-2022 10-Q
9 05-11-2022 04-03-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-12-2021 10-03-2021 10-Q
12 08-12-2021 07-04-2021 10-Q
13 05-13-2021 04-04-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-27-2020 10-Q
16 08-06-2020 06-28-2020 10-Q
17 05-07-2020 03-29-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-07-2019 09-29-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 07-01-2018 10-Q
25 05-10-2018 04-01-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 11-09-2017 10-01-2017 10-Q
28 08-10-2017 07-02-2017 10-Q
29 05-11-2017 04-02-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-10-2016 10-02-2016 10-Q
32 08-11-2016 07-03-2016 10-Q
33 05-12-2016 04-03-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-05-2015 09-27-2015 10-Q
36 08-06-2015 06-28-2015 10-Q
37 05-07-2015 03-29-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-06-2014 09-28-2014 10-Q
40 08-07-2014 06-29-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 how-to-earn-500-a-month-from-pfizer-stock

New York-based Pfizer currently has a dividend yield of 5.96% — a quarterly dividend of 42 cents a share ($1.68 a year).

 pfizers-lorbrena-crown-study-shows-majority-of-patients-with-alk-positive-advanced-lung-cancer-living-beyond-5-years-without-disease-progression

An unprecedented 60% of patients remain alive without disease progression after five yearsUpdated results show continued 81% re...

 are-boomers-crashing-the-economy-or-saving-it-why-investors-are-perplexed-and-what-you-can-do-to-prepare

Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest w...

 sarepta-downgraded-as-fda-decision-date-approaches-shares-up-50-over-last-six-months

RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recen...

 jim-cramer-celestica-makes-a-comeback-sell-this-movie-theater-stock

Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter...

 zantac-verdict-jury-finds-no-link-to-colon-cancer-in-initial-trial-gsk-and-boehringer-prevail-in-first-zantac-cancer-lawsuit

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies d...

 biden-administration-urges-supreme-court-review-in-terrorism-funding-lawsuit-against-pharma-companies

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medi...

 pfizers-path-to-profit-a-look-at-pfe-stock-as-drugmaker-rolls-out-15b-in-cost-reductions

Pfizer launched a $1.5 billion cost reduction program to enhance operational efficiencies and cut costs amid declining sales. S...

 pfizer-initiates-multi-year-cost-reduction-plan-targeting-15b-savings-by-2027

The company disclosed the new program in a filing with the Securities and Exchange Commission.

 experts-predict-rise-in-covid-19-cases-vaccine-stocks-climb

Experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of Covi...

 pfizer-says-in-q2-2024-it-is-launching-a-multi-tear-program-to-reduce-our-cost-of-goods-sold-first-phase-of-multi-year-program-to-reduce-cost-of-goods-sold-is-expected-to-deliver-savings-of-15b-by-end-of-2027-costs-will-be-recorded-primarily-in-2024-with-cash-outlays-expected-in-2025-and-2026-one-time-costs-to-achieve-savings-associated-with-first-phase-of-program-are-expected-to-be-about-17b

- Reuters

Core News & Articles

https://www.nbcnews.com/now/video/disease-experts-predict-a-small-rise-in-covid-cases-this-summer-211393605953 Disease experts ...

 hospira-inc-issues-a-voluntary-nationwide-recall-for-buprenorphine-hydrochloride-injection-carpuject-units-and-labetalol-hydrochloride-injection-usp-carpuject-units-due-to-the-potential-for-incomplete-crimp-seals---press-release

https://www.pfizer.com/news/announcements/hospira-inc-issues-voluntary-nationwide-recall-buprenorphine-hydrochloride

 gsk-concealed-risk-associated-with-discontinued-heart-burn-drug-zantac-whistleblower-lawsuit-claims

Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. Thi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION